Belite Bio, Inc (BLTE)


+0.92 (+3.39%)
Symbol BLTE
Price $28.02
Beta 0.000
Volume Avg. 0.01M
Market Cap 696.785M
Shares () -
52 Week Range 8.8-44.7
1y Target Est -
DCF Unlevered BLTE DCF ->
DCF Levered BLTE LDCF ->
ROE -143.25% Strong Sell
ROA -18.93% Sell
Operating Margin -
Debt / Equity 2.87% Neutral
P/E -90.39 Strong Sell
P/B 13.60 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest BLTE news

Dr. Yu-Hsin Lin M.B.A., Ph.D.
NASDAQ Capital Market

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.